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Abstract
Background: Breast cancer is a polygenetic disorder with a complex inheritance pattern. Single nucleotide polymorphisms
(SNPs), the most common genetic variations, influence not only phenotypic traits, but also interindividual predisposition to
disease, treatment outcomes with drugs and disease prognosis. The co-stimulatory molecule CD40 plays a prominent role in
immune regulation and homeostasis. Accumulating evidence suggests that CD40 contributes to the pathogenesis of
cancer. Here, we set out to test the association between polymorphisms in the CD40 gene and breast carcinogenesis and
tumor pathology.
Methodology and Principal Findings: Four SNPs (rs1800686, rs1883832, rs4810485 and rs3765459) were genotyped by the
polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method in a case-control study including
591 breast cancer patients and 600 age-matched healthy controls. Differences in the genotypic distribution between breast
cancer patients and healthy controls were analyzed by the Chi-square test for trends. Our preliminary data showed a
statistically significant association between the four CD40 gene SNPs and sporadic breast cancer risk (additive P=0.0223,
0.0012, 0.0013 and 0.0279, respectively). A strong association was also found using the dominant, recessive and
homozygote comparison genetic models. In the clinical features analysis, significant associations were observed between
CD40 SNPs and lymph node metastasis, human epidermal growth factor receptor 2 (C-erbB2), estrogen receptor (ER),
progesterone receptor (PR) and tumor protein 53 (P53) statuses. In addition, our haplotype analysis indicated that the
haplotype Crs1883832Grs4810485, which was located within the only linkage disequilibrium (LD) block identified, was a
protective haplotype for breast cancer, whereas Trs1883832Trs4810485 increased the risk in the studied population, even after
correcting the P value for multiple testing (P=0.0337 and 0.0430, respectively).
Conclusions and Significance: Our findings primarily show that CD40 gene polymorphisms contribute to sporadic breast
cancer risk and have a significant association with clinicopathological features among Chinese Han women from the
Heilongjiang Province.
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Introduction
Breast cancer is a major cause of cancer death among women
worldwide. Recent research has suggested that variations in some
immune regulatory genes drive interindividual differences in
sporadic breast cancer susceptibility [1]. CD40 is a crucial member
of the group of co-stimulating molecules, orchestrating both
humoral and cell-mediated immune responses. The interaction
between the CD40 protein and its ligand CD154 triggers a number
of signaling eventsaffectingantigen-presentingcell (APC) activity,T
cell costimulation, and B cell growth and survival [2]. Moreover,
CD40 is not only expressed on immune cells but is also present on
endothelial cells and fibroblasts [3–6]. Nearly 75% of all epithelial
malignancies examined to date may express a high level of CD40,
indicating the complex functions of this molecule in human disease
pathogenesis. CD40 is a member of the tumor necrosis superfamily
and is located on chromosome 20q12-13.2. The CD40 pathway
plays an important role in anti-tumor responses by promoting
cytotoxic lymphocyte (CTL) responses and the differentiation of
helper T cells into cells with the Th1 phenotype [7]. In recent years,
some CD40 agonists have been demonstrated to be effective against
human malignancies [8,9]. Conversely, other studies have shown
thatCD40maycontributetotumorgrowthandmetastasis[10].For
instance, CD40 signaling in endothelial cells results in less apoptosis
and increased proliferation, which may promote tumor growth
through angiogenesis [11–13]. In addition, chemokines, such as IL-
10 and VEGF, induced by the CD40-CD153 interaction on various
cell types are all thought to have roles in malignant cell metastasis
[7]. Currently, the mechanisms of the multifaceted roles of CD40 in
cancer are still not completely understood.
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susceptibility to breast cancer. A recent report in a Turkish
population study showed there is an association between the
rs1883832 TT genotype and susceptibility to breast cancer [14].
Furthermore, some functional studies have reported that
rs1883832 is associated with enhanced CD40 translational
efficiency and influences the levels of CD40 molecules on the
surfaces of B lymphocytes and dendritic cells and the level of
circulating soluble CD40 [15,16]. In addition, CD40 polymor-
phisms have roles in predicting infection- and autoimmunity-
associated diseases, such as Grave’s disease and coronary artery
calcification [16,17].
Based on these data, we speculated that SNPs in CD40
independently or synergistically influence the susceptibility to
sporadic breast cancer. To investigate this hypothesis, a case-
control study was conducted in a Chinese Han population from
Heilongjiang Province, located in the northeastern part of China.
Results
Frequencies of genotypes and alleles
The distribution of the CD40 genotypes in our studied
population is given in Table 1. To ensure quality control of the
genotyping results, samples that failed to be genotyped in the first
round of genotyping were run a second time. Samples for which
genotyping data was successfully obtained from the second round
were then repeated once, whereas samples for which the genotypes
remained uninterpretable were classified as missing data. Further-
more, we randomly selected 10% of the samples to submit to
direct sequencing, and the results were consistent with the PCR-
RFLP results. In total, 1177 samples (98.82%) of the rs1800686
polymorphism, 1165 samples (97.82%) of the rs1883832 poly-
morphism, 1178 samples (98.91%) of the rs4810485 polymor-
phism and 1157 samples (97.15%) of the rs3765459 polymorphism
were successfully tested in this study. For all of the genotyped
SNPs, there was no deviation from Hardy-Weinberg equilibrium
(P.0.05), and no minor allele frequency was less than 10%.
Missing data accounted for less than 10% of all data.
As shown in Table 1 and Table 2, the SNPs genotyped in this
study showed a statistically significant association with breast
cancer under different genetic models. For the rs1800686
polymorphism, we observed a higher prevalence of A alleles
(P=0.0275, OR=1.215, 95%CI [1.022, 1.445]) in breast cancer
patients than in controls. Statistical significance was also found
using the additive genetic model (GG vs. GA vs. AA, P=0.0223),
the recessive genetic model (AA vs. GG+GA, P=0.0060) and the
homozygote comparison (AA vs. GG, P=0.0071). Strong
associations with breast cancer risk were found for rs1883832
and rs4810485 respectively in the additive genetic model (CC vs.
CT vs. TT, P=0.0012; GG vs. GT vs. TT, P=0.0013,
respectively) and in the dominant genetic model (TT+CT vs.
CC, P=0.0004, TT+GT vs. GG, P=0.0005, respectively). For
the rs1883832 and rs4810485 polymorphisms, different distribu-
tions were also observed for the rs1883832 T allele and the
rs4810485 T allele between patients and controls, even after
correcting the P value for multiple testing using Haploview with
10,000 permutations (P=0.0193, OR=1.264 95%CI [1.066,
1.499]; P=0.0250, OR=1.252 95%CI [1.057,1.482], respec-
tively). Further, in the analysis of rs3765459, the A allele had a
higher prevalence among patients (P=0.0250, OR=1.221,
95%CI [1.025, 1.454]), and a genotype analysis using different
genetic models (additive, GG vs. GA vs. AA, P=0.0279;
recessive, AA vs. GG+GA, P=0.0082; homozygote comparison,
AA vs. GG, P=0.0081) also indicated a significant association
between this SNP and breast cancer risk.
Haplotype analysis
As shown in Figure S1, we found that rs1883832 and
rs4810485 (D9=0.94, R
2=0.87) belonged to the only LD block
identified using the Haploview program based on the Solid Spine
of LD method. Table 3 lists the haplotypes with frequencies
§1%. Two of the SNPs (rs1883832 and rs4810485) genotyped
were within the only defined haplotype block, which was
significantly associated with sporadic breast cancer risk (details
in Table 3).
Table 1. Genotyping of CD40 gene SNPs in breast cancer patients and controls.
Reference
SNP ID Geno -type Frequency no. (%)
Additive
P value
Dominant
P value
Recessive
P value
Homozygote
comparison
P value
Patients Controls
rs1800686 GG 265(45.69%) 293(49.08%) 0.0223 0.2444 0.0060 0.0071
AG 234(40.34%) 251(42.04%)
AA 81(13.97%) 53(8.88%)
rs1883832 CC 213(36.66%) 274(46.92%) 0.0012 0.0004 0.8316 0.1438
CT 297(51.12%) 241(41.27%)
TT 71(12.22%) 69(11.82%)
rs4810485 GG 206(35.64%) 274(45.67%) 0.0013 0.0005 0.8777 0.1500
GT 299(51.73%) 252(42.00%)
TT 73(12.63%) 74(12.33%)
rs3765459 GG 258(45.10%) 286(48.89%) 0.0279 0.1973 0.0082 0.0081
AG 235(41.08%) 247(42.22%)
AA 79(13.81%) 52(8.89%)
Significant values (P,0.05) are in bold.
doi:10.1371/journal.pone.0023762.t001
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The clinical features of the 591 breast cancer patients are
summarized in Table 4. The correlation between polymorphisms
of CD40 and a series of clinicopathologic features, including
histological grade, tumor size, lymph node metastasis and the
statuses of ER, PR, C-erbB2 and P53 were analyzed in this study.
Detailed results of the statistically significant associations are
presented in Table S1, Table S2, Table S3, Table S4 and Table
S5 respectively in the Supporting Information section. The most
significant associations were observed in analysis of the associated
between rs1800686 and the ER and PR statuses. Following
correction of the P value for multiple testing using Haploview, the
rs1800686 G allele remained statistically more frequent in ER/PR
positive cases (ER, P=0.0015; PR, P=0.0027, respectively). In
the breast cancer patient group, the rs1883832 T allele seemed to
provide a protective effect against lymph node metastasis
(P=0.0479), and a statistically significant association was found
using the recessive model (TT vs. CC+CT, P=0.0458) and the
homozygote comparison (TT vs. CC, P=0.0282). We further
identified the association between the four SNPs genotyped and
the C-erbB2 statuses of breast cancer patients. As shown in Table
S4, rs1800686 and rs3765459 were associated with the C-erbB2
statuses of breast cancer patients. Breast cancer patients with the
rs1800686 A allele or the rs3765459 A allele had an increased risk
of a C-erbB2 positive status compared with patients with the
rs1800686 A allele or the rs3765459 A allele (P=0.0249 and
P=0.0361, respectively). Table S5 presents the relationship
between SNPs and the P53 status, and a statistically significant
association was found in the rs1800686 allelic P value (P=0.0223),
the rs1800686 recessive genetic model (AA vs. GA+GG,
P=0.0423), the rs1800686 homozygote comparison (AA vs. GG,
P=0.0247), the rs3765459 recessive genetic model (AA vs.
GA+GG, P=0.0491) and the rs3765459 homozygote comparison
(AA vs. GG, P=0.0428). However, no relationships were found
for tumor size and histological grade. Overall, these date indicate
that rs1800686 and rs3765459 polymorphisms are associated with
the ER, PR, C-erbB2 and P53 statuses in breast cancer patients,
whereas the rs1883832 and rs4810485 polymorphisms may be
involved in breast cancer lymph node metastasis.
Discussion
The CD40 pathway has been recognized as a major component
of the anti-tumor response and holds promise as a novel target for
therapies for advanced human malignancies [18]. However,
accumulating evidence has indicated that CD40 may contribute
to tumor proliferation and escape through its special transduction
pathway, indicating the multifaceted biological properties of CD40
in cancer [7]. Due to the complex functions of the CD40 pathway
in the prognosis of cancer, polymorphisms of the CD40 gene that
have crucial roles in the translational efficiency of the CD40
protein may affect the risk and prognosis of breast cancer in
Table 2. Alleles of the four SNPs in CD40 gene.
Reference SNP ID Allele Frequency No. (%) P value OR (95% CI)
Patients (n=591) Controls (n=600)
rs1800686 G 764(65.86%) 837(70.10%)
A/G A 396(34.14%) 357(29.90%) 0.0275 1.215 (1.022,1.445)
rs1883832 C 723(62.22%) 789(67.55%)
C/T T 439(37.78%) 379(32.45%) 0.0070
a 1.264 (1.066,1.499)
rs4810485 G 711(61.51%) 800(75.00%)
G/T T 445(38.49%) 400(25.00%) 0.0090
b 1.252 (1.057,1.482)
rs3765459 G 751(65.65%) 819(70.00%)
A/G A 393(34.35%) 351(30.00%) 0.0250 1.221(1.025,1.454)
Significant values (p,0.05) are in bold.
aP=0.0193,
bP=0.0250 after correcting P value for multiple testing by Haploview program using 10,000 permutations.
Abbreviations: OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0023762.t002
Table 3. CD40 haplotype frequencies in breast cancer patients and controls.
Reference SNP ID Haplotype Frequency Haplotype Frequency P value
rs1883832 rs4810485 Patients Controls
C G 0.630 60.48% 65.53% 0.0107
a
T T 0.340 36.40% 31.67% 0.0150
b
C T 0.017 1.79% 1.67% 0.8131
T G 0.012 1.33% 1.13% 0.6555
Significant values (P,0.05) are in bold.
aP=0.0337,
bP=0.0430 after correcting P value for multiple testing by Haploview using 10,000 permutations.
doi:10.1371/journal.pone.0023762.t003
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rs4810485 and rs3765459) were included in our case-control
study. And our results indicate that some of the alleles, genotypes
and haplotypes of the CD40 gene are associated with the risk and
the clinicopathological features of breast cancer.
In this study, we observed that the rs1800686 AA genotype may
increase the risk of breast cancer. The rs1800686 SNP is located at
the 59 near gene region of the CD40 gene, where mutations can
modulate CD40 promoter activity. Thus, it is probable that the
rs1800686 AA genotype contributes to breast carcinogenesis by
lowing CD40 levels on immune cells to suppress the anti-tumor
responses. The frequencies of the rs1883832 C allele and the
rs4810485 G allele were lower in patients than in controls, even
after correcting the P value for multiple testing, suggesting that
these two alleles play a protective role in breast cancer. As we
know, rs1883832 coincides into the Kozak consensus sequence
[19]. Previous functional studies have revealed that individuals
with the rs1883832 TT genotype have lower circulating soluble
CD40 levels and reduced levels of CD40 on the surfaces of
monocyte-derived activated dendritic cells and B cells [15,16].
Moreover, the rs1883832 CC genotype which could enhance
CD40 translational efficiency has been shown to induce the
development of autoimmune diseases, such as Grave’s disease
[16]. The rs4810485 SNP, which is located at intron 1, can play
an important role in the splicing processes to regulate CD40 gene
expression. It is probable that the rs1883832 T allele located at the
Kozak consensus and that the rs4810485 T allele is located at
intron 1, which may reduce CD40 expression on immune cell
surfaces by hindering the stabilization of the mRNA-ribosome
complex [14] and by inducing aberrant splicing, respectively,
preventing immune cells from finding and eliminating precancer-
ous cells, thus increasing the breast cancer risk. A similar result was
also found for rs3765459, located in intron 8, where mutations
may also induce aberrant splicing due to the disruption of the
splice site.
In the clinical features analysis, we found that CD40
polymorphisms were associated the clinicopathological features
of the patients. For rs1800686 and rs3765459, statistically
significant differences were found for PR-positive, ER-positive,
C-erbB2-positive cases compared with the negative controls.
Steroid hormone receptors influence the disease-free and overall
survival of breast cancer patients and are considered to be
predictive markers of endocrine therapy [20–22]. The expression
of C-erbB2 is associated with the tumor metastasis [23,24]. Thus,
the genotypes of rs1800686 and rs3765459 may be good markers
to predict the prognosis of breast cancer and the effectiveness of
pharmaceutical treatment. Interestingly, although the frequencies
of the rs1883832 T and rs4810485 T alleles were found to be
higher among breast cancer patients, the frequencies were lower
among patients with lymph node involvement. These results
indicate that the rs1883832 T and rs4810485 T alleles were risk
factors for breast cancer occurrence but protective factors for
lymph node metastasis.
The linkage disequilibrium (LD) among the four CD40
polymorphic loci was assessed using Haploview. One LD block
including rs1883832 and rs4810485 was identified, which was
significantly associated with sporadic breast cancer risk. The
haplotype Crs1883832Grs4810485 was a protective haplotype, whereas
Trs1883832Trs4810485 increased the breast cancer risk in our
population, even after correcting the P value for multiple testing
(P=0.0337 and 0.0430, respectively). These haplotypes may also
be meaningful in the pathology of breast cancer in our population.
We investigated the association between CD40 gene polymor-
phisms and the sporadic breast cancer. CD40 gene polymorphisms
appear to contribute to sporadic breast cancer risk and had a
significant association with clinicopathological features among
Chinese Han women from northeast China. However, larger
epidemiological studies with ethnically diverse populations as well
as the basic functions of CD40 gene mutations need to be further
conducted.
Materials and Methods
Human specimen collection
Peripheral blood samples were obtained from 591 patients
referred at the Department of Abdominal Surgery. (the Third
Affiliated Hospital of Harbin Medical University, Heilongjiang
Province). The 591 patients consisted in our study are ranged from
20 to 78 years old (mean age at 49.867.4 years), who were all
diagnosed by surgical and pathological symptoms. Each patient’s
Table 4. Clinicopathologic information of breast cancer
patients (n=591).
Clinicopathologic information Case, No. (%)
Tumor Type
IDC 510(86.29)
MC 13(2.20)
Intraductal carcinoma 31(5.25)
Mucinous adenocarcinoma 4(0.68)
Others 33(5.58)
Tumor Size
With the diameter less than 2 cm 205(34.69)
With the diameter of 2 to 5 cm 266(45.01)
With the diameter more than 5 cm 35(5.92)
Unknown 85(14.38)
LN involvement
Positive 259(43.82)
Negative 322(54.48)
Unknown 10(1.69)
ER
Positive 288(48.73)
Negative 210(35.53)
Unknown 93(15.74)
PR
Positive 361(61.08)
Negative 135(22.84)
Unknown 95(16.07)
P53
Positive 116(19.63)
Negative 288(48.73)
Unknown 187(31.64)
C-erbB2
Positive 156(26.40)
Negative 338(57.19)
Unknown 97(16.41)
Abbreviations: IDC, infiltrative ductal carcinoma; MC, medullary carcinoma; LN,
lymph node; ER, estrogen receptor; PR, progesterone receptor; P53, tumor
protein 53; C-erbB2, human epidermal growth factor receptor 2.
doi:10.1371/journal.pone.0023762.t004
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healthy controls were recruited randomly from community
volunteers. All of the healthy controls were frequency matched
to the patients by age (mean age at 46.368.4 years) and did not
have a history of personal or familial malignancy or autoimmune
disorders. The patients were recruited from 2005 to 2010, and the
healthy controls were recruited from 2005 to 2009. This study was
conducted in the Heilongjiang Province in northeastern China.
This research has the approval instruments of the institutional
ethical committees of the Third Affiliated Hospital of Harbin
Medical University and Harbin Medical University. All of the
volunteers gave written confirmed consent.
DNA extraction and genotyping
5 ml frozen whole blood was taken to extract the genomic DNA
using the Universal Genomic DNA Extraction Kit, version 3.0
(TaKaRa, Japan) according to the manufacturer’s protocol. All the
genotyping was performed using the polymerase chain reaction
restriction fragment length polymorphism (PCR-RFLP) assay. The
primers and PCR programs for CD40 PCR-RFLP genotyping are
shown in Table S6. The PCR reaction mixture contained 0.3 mg
genomic DNA, 16PCR buffer (Mg
2+ Free), 0.3 mM MgCl2,
0.2 mM dNTPs, 2 U Taq DNA polymerase (Takara, Japan),
0.1 mmol of each primer (Shenggong, China) and ddH2O in a final
volume of 25 mL. The regions containing polymorphisms were
amplified by PCR with a T-Gradient Thermoblock PCR System
(BioRad, USA). The restriction enzymes for each SNP were BssSI
(rs1800686), NcoI (rs1883832), MspI (rs4810485) and PflmI
(rs3765459). For rs1800686/rs3765459, 5 mL of PCR-amplified
product was incubated at 37uC for 6–8 h with 0.5 mL of restriction
enzyme (BssSI 4000 U/mL, PflmI 8000 U/mL, NEB, USA),
50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl2,1 m M
dithiothreitol, 0.1% BSA and ddH2O in a final volume of
10 mL. For rs1883832, 4 mL of PCR-amplified product was
incubated at 37uC for 6–8 h with 0.5 mL of restriction enzyme
(NcoI 10,000 U/ml, NEB, USA), 50 mM Tris-HCl, 100 mM
NaCl, 10 mM MgCl2, 1 mM dithiothreitol, and ddH2O in a final
volume of 10 mL. For rs4810485, 4 mL of PCR-amplified product
was incubated at 37uC for 6–8 h with 0.5 mL of restriction enzyme
(MspI 20,000 U/ml, NEB, USA), 20 mM Tris-acetate, 50 mM
postassium acetate, 10 mM magnesium acetate, 1 mM dithiothre-
itol, and ddH2O in a final volume of 10 mL. The digested
fragment lengths for each SNP were as follows: rs1800686 (G:
72+378 bp, A: 450 bp), rs1883832 (C: 61+221 bp, T: 282 bp),
rs4810485 (G: 18+148+112 bp, T: 278 bp) and rs3765459 (A:
265+156 bp, G: 421 bp). The results of the 3% agarose gel
electrophoresis were analyzed using a Gel Imaging Analysis
System and TV lens (Computar, Japan). After PCR-RFLP
analysis, purified PCR products of 10% of samples were
sequenced directly using an ABI-3730xp automatic DNA
sequencer (Applied Biosystems).
Statistical analysis
The deviation from Hardy-Weinberg equilibrium was deter-
mined using a goodness-of-fit Chi-square test to compare the
observed genotype frequencies with the expected frequencies
among the healthy controls. The polymorphisms were excluded if
they deviated from HWE if the minor allele frequency less than
10% or if the missing data comprised more than 10% of the total
data. The genotype frequencies of the subjects determined using
different genetic models (additive, dominant, recessive and
homozygote comparison) was analyzed using the Chi-square test.
Haploview was used to infer the haplotype and allele frequencies
based on the observed genotypes. To determine the significance
corrected for the multiple testing bias, we ran 10,000 permutations
to determine the P value using Haploview. All data were analyzed
with SPSS (Version 17.0; SPSS, Chicago, Illinois) and Haploview
(version 4.1) (http://www.broad.mit.edu/mpg/haploview/). The
threshold for significance was P,0.05, and the relative risks
associated with rare alleles, genotypes and haplotypes were
estimated as odds ratios (ORs) with 95% confidence intervals (CIs).
Supporting Information
Figure S1 Linkage disequilibrium (LD) block defined by the
Haploview program (Linkage disequilibrium block defined by the
Haploview program based on the Solid Spine of LD method.
Pairwise LD coefficients D96100 are shown in each cell. The
standard color scheme was applied for LD color display.)
(TIF)
Table S1 Significant associations between CD40 SNPs and ER
status in patients.
(DOC)
Table S2 Significant associations between CD40 SNPs and PR
status in patients.
(DOC)
Table S3 Significant associations between CD40 SNPs and LN
involvement status in patients.
(DOC)
Table S4 Significant associations between CD40 SNPs and C-
erbB2 status in patients.
(DOC)
Table S5 Significant associations between CD40 SNPs and P53
status in patients.
(DOC)
Table S6 Primers, PCR programs, restriction enzyme and
restriction fragments for CD40 PCR-RFLP genotyping.
(DOC)
Acknowledgments
We thank all patients and healthy volunteers for providing blood samples.
We are grateful for the collaboration received from the participating
hospitals and their staff.
Author Contributions
Conceived and designed the experiments: DL PD. Performed the
experiments: CS LD YW. Analyzed the data: YW FZ XF. Wrote the
paper: CS LD.
References
1. Pal R, Gochhait S, Chattopadhyay S, Gupta P, Prakash N, et al. (2011)
Functional implication of TRAIL 2716 C/T promoter polymorphism on its in
vitro and in vivo expression and the susceptibility to sporadic breast tumor.
Breast Cancer Res Treat 126: 333–343.
2. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, et al. (2009) Molecular
mechanism and function of CD40/CD40L engagement in the immune system.
Immunol Rev 229: 152–172.
3. Purkerson JM, Smith RS, Pollock SJ, Phipps RP (2005) The TRAF6, but not the
TRAF2/3, binding domain of CD40 is required for cytokine production in
human lung fibroblasts. Eur J Immunol 35: 2920–2928.
4. Tan J, Town T, Mori T, Obregon D, Wu Y, et al. (2002) CD40 is expressed and
functional on neuronal cells. EMBO J 21: 643–652.
5. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW (1998) CD40 and
epithelial cells: across the great divide. Immunol Today 19: 502–506.
CD40 Gene Polymorphisms on Sporadic Breast Cancer
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e237626. Hollenbaugh D, Mischel-Petty N, Edwards CP, Simon JC, Denfeld RW, et al.
(1995) Expression of functional CD40 by vascular endothelial cells. J Exp Med
182: 33–40.
7. Murugaiyan G, Martin S, Saha B (2007) CD40-induced countercurrent conduits
for tumor escape or elimination? Trends Immunol 28: 467–473.
8. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, et al.
(2007) Clinical activity and immune modulation in cancer patients treated with
CP-870, 893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25:
876–883.
9. Gomes EM, Rodrigues MS, Phadke AP, Butcher LD, Starling C, et al. (2009)
Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene
construct in human breast cancer cells. Clin Cancer Res 15: 1317–1325.
10. Baxendale AJ, Dawson CW, Stewart SE, Mudaliar V, Reynolds G, et al. (2005)
Constitutive activation of the CD40 pathway promotes cell transformation and
neoplastic growth. Oncogene 24: 7913–7923.
11. Deregibus MC, Buttiglieri S, Russo S, Bussolati B, Camussi G (2003) CD40-
dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates
endothelial cell survival and in vitro angiogenesis. J Biol Chem 278:
18008–18014.
12. Flaxenburg JA, Melter M, Lapchak PH, Briscoe DM, Pal S (2004) The CD40-
induced signaling pathway in endothelial cells resulting in the overexpression of
vascular endothelial growth factor involves Ras and phosphatidylinositol 3-
kinase. J Immunol 172: 7503–7509.
13. Melter M, Reinders ME, Sho M, Pal S, Geehan C, et al. (2000) Ligation of
CD40 induces the expression of vascular endothelial growth factor by
endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 96:
3801–3808.
14. Dolen Y, Yilmaz G, Esendagli G, Guler NE, Guc D (2010) CD40 -1C.T single
nucleotide polymorphism and CD40 expression on breast tumors. Cytokine 50:
243–244.
15. Skibola CF, Nieters A, Bracci PM, Curry JD, Agana L, et al. (2008) A functional
TNFRSF5 gene variant is associated with risk of lymphoma. Blood 111:
4348–4354.
16. Jacobson EM, Concepcion E, Oashi T, Tomer Y (2005) A Graves’ disease-
associated Kozak sequence single-nucleotide polymorphism enhances the
efficiency of CD40 gene translation: a case for translational pathophysiology.
Endocrinology 146: 2684–2691.
17. Jacobson EM, Huber AK, Akeno N, Sivak M, Li CW, et al. (2007) A CD40
Kozak sequence polymorphism and susceptibility to antibody-mediated
autoimmune conditions: the role of CD40 tissue-specific expression. Genes
Immun 8: 205–214.
18. Loskog AS, Eliopoulos AG (2009) The Janus faces of CD40 in cancer. Semin
Immunol 21: 301–307.
19. Kozak M (1987) An analysis of 59-noncoding sequences from 699 vertebrate
messenger RNAs. Nucleic Acids Res 15: 8125–8148.
20. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive
analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative,
and HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: a population-based study from the California cancer Registry.
Cancer 109: 1721–1728.
21. Lee JS, Lo PK, Fackler MJ, Argani P, Zhang Z, et al. (2007) A comparative
study of Korean with Caucasian breast cancer reveals frequency of methylation
in multiple genes correlates with breast cancer in young, ER, PR-negative breast
cancer in Korean women. Cancer Biol Ther 6: 1114–1120.
22. Stendahl M, Ryde ´n L, Nordenskjo ¨ld B, Jo ¨nsson PE, Landberg G, et al. (2006)
High progesterone receptor expression correlates to the effect of adjuvant
tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12:
4614–4618.
23. Beenken SW, Grizzle WE, Crowe DR, Conner MG, Weiss HL, et al. (2001)
Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and
p53. Ann Surg 233: 630–638.
24. Shimizu C, Fukutomi T, Tsuda H, Akashi-Tanaka S, Watanabe T, et al. (2000)
c-erbB-2 protein overexpression and p53 immunoreaction in primary and
recurrent breast cancer tissues. J Surg Oncol 73: 17–20.
CD40 Gene Polymorphisms on Sporadic Breast Cancer
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23762